Sophia Li1, Christopher Reynaert2, Annie Ling Su3, Sonja Sawh4. 1. , PharmD, RPh, was, at the time this study was initiated, with the Pharmacy Department, London Health Sciences Centre, London, Ontario. She is now is a Clinical Pharmacist with the Pharmacy Department, Providence Healthcare, Vancouver, British Columbia. 2. , BScPhm, RPh, is a Pharmacist with the Pharmacy Department, London Health Sciences Centre, London, Ontario. 3. is a candidate in the PharmD program of the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia. 4. , BScPhm, RPh, ACPR, was, at the time this review was initiated, the Evidence-Based Medicine Pharmacist with the Pharmacy Department, London Health Sciences Centre, London, Ontario. She is now Clinical Director, Pharmacy Services, with Mohawk Medbuy Corporation, London, Ontario.
Abstract
BACKGROUND: Crohn disease is an inflammatory bowel disease with intermittent symptoms relating to damage to the gastrointestinal tract. Compared with adult-onset Crohn disease, the childhood-onset form is more likely to be severe. Infliximab has shown efficacy in adult patients. OBJECTIVE: To examine the efficacy and safety of infliximab in pediatric Crohn disease, by means of a systematic review. DATA SOURCES: Three databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) and regulatory documents were searched from inception to December 2017. Clinical trial registries, conference abstracts, and reference lists were searched to March 2018. STUDY SELECTION AND DATA EXTRACTION: Randomized controlled trials (RCTs) and prospective cohort studies that compared infliximab with active control were included in the analysis. Two reviewers independently performed screening, extracted data, and assessed risk of bias. The primary outcomes were induction and maintenance of endoscopic remission and severe adverse effects. DATA SYNTHESIS: Three eligible RCTs comparing different dose regimens, 16 prospective cohort studies comparing infliximab with other therapies (adalimumab, exclusive enteral nutrition, or standard of care), and 3 prospective cohort studies comparing different infliximab regimens were identified. Meta-analysis of the RCTs showed no significant difference between infliximab every 8 weeks compared with longer intervals for maintenance of clinical remission (risk ratio [RR] 1.76, 95% confidence interval [CI] 0.98-3.19). Meta-analyses of the prospective cohort studies showed no significant differences between infliximab and adalimumab for maintenance of endoscopic remission (RR 1.07, 95% CI 0.60-1.92), between infliximab and exclusive enteral nutrition for induction of clinical remission (RR 1.09, 95% CI 0.82-1.45), or between infliximab and standard of care for maintenance of clinical remission at 6 and 12 months (RR 1.12, 95% CI 0.58-2.17, and RR 1.24, 95% CI 0.84-1.84, respectively). CONCLUSIONS: Current evidence suggested comparable efficacy for infliximab and other therapies; however, the available literature was limited by risk of bias and small sample size. Further prospective studies are needed to confirm the efficacy and safety of this drug in pediatric Crohn disease.
BACKGROUND: Crohn disease is an inflammatory bowel disease with intermittent symptoms relating to damage to the gastrointestinal tract. Compared with adult-onset Crohn disease, the childhood-onset form is more likely to be severe. Infliximab has shown efficacy in adult patients. OBJECTIVE: To examine the efficacy and safety of infliximab in pediatric Crohn disease, by means of a systematic review. DATA SOURCES: Three databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) and regulatory documents were searched from inception to December 2017. Clinical trial registries, conference abstracts, and reference lists were searched to March 2018. STUDY SELECTION AND DATA EXTRACTION: Randomized controlled trials (RCTs) and prospective cohort studies that compared infliximab with active control were included in the analysis. Two reviewers independently performed screening, extracted data, and assessed risk of bias. The primary outcomes were induction and maintenance of endoscopic remission and severe adverse effects. DATA SYNTHESIS: Three eligible RCTs comparing different dose regimens, 16 prospective cohort studies comparing infliximab with other therapies (adalimumab, exclusive enteral nutrition, or standard of care), and 3 prospective cohort studies comparing different infliximab regimens were identified. Meta-analysis of the RCTs showed no significant difference between infliximab every 8 weeks compared with longer intervals for maintenance of clinical remission (risk ratio [RR] 1.76, 95% confidence interval [CI] 0.98-3.19). Meta-analyses of the prospective cohort studies showed no significant differences between infliximab and adalimumab for maintenance of endoscopic remission (RR 1.07, 95% CI 0.60-1.92), between infliximab and exclusive enteral nutrition for induction of clinical remission (RR 1.09, 95% CI 0.82-1.45), or between infliximab and standard of care for maintenance of clinical remission at 6 and 12 months (RR 1.12, 95% CI 0.58-2.17, and RR 1.24, 95% CI 0.84-1.84, respectively). CONCLUSIONS: Current evidence suggested comparable efficacy for infliximab and other therapies; however, the available literature was limited by risk of bias and small sample size. Further prospective studies are needed to confirm the efficacy and safety of this drug in pediatric Crohn disease.
Authors: Edwin F de Zoeten; Brad A Pasternak; Peter Mattei; Robert E Kramer; Howard A Kader Journal: J Pediatr Gastroenterol Nutr Date: 2013-09 Impact factor: 2.839
Authors: Dale Lee; Robert N Baldassano; Anthony R Otley; Lindsey Albenberg; Anne M Griffiths; Charlene Compher; Eric Z Chen; Hongzhe Li; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Frederic D Bushman; Gary D Wu; James D Lewis Journal: Inflamm Bowel Dis Date: 2015-08 Impact factor: 5.325
Authors: Marian Pfefferkorn; Georgine Burke; Anne Griffiths; James Markowitz; Joel Rosh; David Mack; Anthony Otley; Subra Kugathasan; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Ryan Carvalho; Wallace Crandall; David Keljo; T D Walters; Neal LeLeiko; Jeffrey Hyams Journal: J Pediatr Gastroenterol Nutr Date: 2009-02 Impact factor: 2.839
Authors: Parambir S Dulai; Kimberly D Thompson; Heather B Blunt; Marla C Dubinsky; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2014-01-22 Impact factor: 11.382
Authors: Thomas D Walters; Mi-Ok Kim; Lee A Denson; Anne M Griffiths; Marla Dubinsky; James Markowitz; Robert Baldassano; Wallace Crandall; Joel Rosh; Marian Pfefferkorn; Anthony Otley; Melvin B Heyman; Neal LeLeiko; Susan Baker; Stephen L Guthery; Jonathan Evans; David Ziring; Richard Kellermayer; Michael Stephens; David Mack; Maria Oliva-Hemker; Ashish S Patel; Barbara Kirschner; Dedrick Moulton; Stanley Cohen; Sandra Kim; Chunyan Liu; Jonah Essers; Subra Kugathasan; Jeffrey S Hyams Journal: Gastroenterology Date: 2013-10-23 Impact factor: 22.682
Authors: F M Ruemmele; G Veres; K L Kolho; A Griffiths; A Levine; J C Escher; J Amil Dias; A Barabino; C P Braegger; J Bronsky; S Buderus; J Martín-de-Carpi; L De Ridder; U L Fagerberg; J P Hugot; J Kierkus; S Kolacek; S Koletzko; P Lionetti; E Miele; V M Navas López; A Paerregaard; R K Russell; D E Serban; R Shaoul; P Van Rheenen; G Veereman; B Weiss; D Wilson; A Dignass; A Eliakim; H Winter; D Turner Journal: J Crohns Colitis Date: 2014-06-06 Impact factor: 10.020